Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories non-GAAP Adjusted Net Earnings ($M) ($M)
Form 8-K Quarterly Earnings Releases (Non-GAAP Reconciliation Tables)
Latest, FY2025
9,040
Period ended Dec 31, 2025
Change on a year earlier
+10.2%
8,200 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Adjusted Net Earnings ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9,040 | +10.2% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 8,200 | +5.1% | SEC Filing (0001628280-26-002982) ↗ |
| FY2023 | Dec 31, 2023 | 7,802 | -17.6% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 9,466 | +1.1% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 9,367 | – | SEC Filing (0001628280-23-001516) ↗ |
Breakdown
What makes up non-gaap adjusted net earnings ($m)
- GAAP Net Earnings — Reconciliation Table ($M)6,524 · FY2025
- Specified Items After-Tax Net Impact ($M)2,516 · FY2025
- Non-GAAP Adjusted Earnings Before Taxes ($M)10,762 · FY2025
- Non-GAAP Adjusted Gross Margin ($M)25,151 · FY2025
- Non-GAAP Adjusted Research & Development Expense ($M)2,830 · FY2025
- Non-GAAP Adjusted Selling, General & Administrative Expense ($M)12,020 · FY2025
- Intangible Assets Amortization Expense ($M)1,682 · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Non-GAAP Adjusted Net Earnings ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/ng-net-inc
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.